Patient Information:

• Name: Ahmed Saad Alghamdi
• Diagnosis: Type-2 Diabetes, Peripheral Vascular Disease, Primary Hypertension
• Date of Birth (D.O.B): August 1, 1955
• Gender: Male
• Country: Saudi Arabia

Treatment: Nerve Growth Factor Therapy for Type-2 Diabetes combined with medications to enhance peripheral circulation and neuronal nutritional support at Beijing Puhua International Hospital (BPIH)

Medical History:
Patient Alghamdi Ahmed Saad, a 59-year-old male, was diagnosed with type-2 diabetes approximately 15 years prior to his current admission. Initial symptoms included polydipsia and polyuria. Despite efforts to manage blood sugar levels with oral anti-diabetic medication, control remained unstable, leading to insulin therapy for the following 5 years.

Medical Condition before Nerve Growth Factor Therapy for Type-2 Diabetes:

• Symptoms:
  • Chronic fatigue
  • Joint pain in limbs
  • Paresthesia ("gloved" feelings) in fingers and toes
  • Poor dietary control of diabetes
  • Frequent urination at night
• Physical examination: Diminished peripheral nerve sensitivity
• Blood sugar records:
  • Fasting morning levels around 10 mmol/L (180 mg/dL)
  • Pre-meal levels around 12 mmol/L (216 mg/dL)
  • Labile blood sugar with fluctuations and peaks over 28 mmol/L (497 mg/dL)

Nerve Growth Factor Therapy for Type-2 Diabetes:

• Treatment: Three rounds of Nerve Growth Factor Therapy combined with systemic circulation improvement and neuronal nutritional supplementation

Medical Condition after Nerve Growth Factor Therapy for Type-2 Diabetes:

• Post-treatment blood sugar levels:
  • Significantly lower under usual oral medication (Glimepiride 6mg daily)
  • Reduced Glimepiride dosage to 3mg/day
  • Reduced Glargine (Lantus) insulin dosage from 20u to 18u/day
• Improved blood sugar control maintained at near-normal levels
• Potential future reduction or cessation of oral medication and insulin therapy

Follow-up:

• Email received on July 23, 2015, from patient's wife:
  • Ahmed Alghamdi has stopped taking insulin and all oral diabetic medications
  • Pancreatic amylase level: 38 (indicating endogenous insulin production)
  • C-peptide level: 1.32 (six months post-treatment)